140 related articles for article (PubMed ID: 38101289)
1. Meta-Analysis on the Association Between DPP-4 Inhibitors and Bone Mineral Density and Osteoporosis.
Huang L; Zhong W; Liang X; Wang H; Fu SE; Luo Z
J Clin Densitom; 2024; 27(1):101455. PubMed ID: 38101289
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus.
Meng J; Yan R; Zhang C; Bai X; Yang X; Yang Y; Feng T; Liu X
Lipids Health Dis; 2023 Dec; 22(1):219. PubMed ID: 38082288
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitors attenuates osteoporosis in patients with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan.
Chang CH; Lu CH; Chung CH; Su SC; Kuo FC; Liu JS; Li PF; Huang CL; Chen KC; Ho LJ; Kuo CC; Chang CY; Lin MS; Liu YC; Chu NF; Lee CH; Hung YJ; Hsieh PS; Lin FH; Hsieh CH; Chien WC
J Chin Med Assoc; 2022 Jul; 85(7):747-753. PubMed ID: 35648138
[TBL] [Abstract][Full Text] [Related]
4. Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population.
Ustulin M; Park SY; Choi H; Chon S; Woo JT; Rhee SY
J Korean Med Sci; 2019 Sep; 34(35):e224. PubMed ID: 31496139
[TBL] [Abstract][Full Text] [Related]
5. Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Gong Y; Bai X; Zhang D; Yang X; Qin Z; Yang Y; Zhou Y; Meng J; Liu X
Lipids Health Dis; 2024 May; 23(1):157. PubMed ID: 38796440
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
7. The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.
Jin Y; Zhao H; Hou Y; Song G
Acta Diabetol; 2020 Oct; 57(10):1129-1144. PubMed ID: 32300876
[TBL] [Abstract][Full Text] [Related]
8. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
Izumi K; Nishie W; Beniko M; Shimizu H
Front Immunol; 2019; 10():1439. PubMed ID: 31297116
[No Abstract] [Full Text] [Related]
9. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis.
Liu X; Men P; Wang B; Cai G; Zhao Z
Lipids Health Dis; 2019 Jun; 18(1):144. PubMed ID: 31208420
[TBL] [Abstract][Full Text] [Related]
10. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
[TBL] [Abstract][Full Text] [Related]
11. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.
Hidayat K; Du X; Shi BM
Osteoporos Int; 2019 Oct; 30(10):1923-1940. PubMed ID: 31134305
[TBL] [Abstract][Full Text] [Related]
12. Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus.
Wei X; Bai Y; Wang Z; Zheng X; Jin Z; Liu X
Diabetol Metab Syndr; 2021 Aug; 13(1):88. PubMed ID: 34446063
[TBL] [Abstract][Full Text] [Related]
13. Association of dipeptidyl peptidase-4 inhibitor use and the risk of asthma development among type 2 diabetes patients.
Li PF; Chung CH; Liu JS; Lu CH; Su SC; Kuo FC; Ho LJ; Chen KC; Su YT; Chu NF; Lee CH; Hsieh CH; Hung YJ; Lin FH; Chien WC; Liang YJ
Ther Adv Respir Dis; 2022; 16():17534666221135320. PubMed ID: 36448591
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review.
Ruan Z; Zou H; Lei Q; Ung COL; Shi H; Hu H
Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):555-574. PubMed ID: 35152812
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis: dipeptidyl peptidase-4 inhibitors and rheumatoid arthritis risk.
Wang M; Li M; Xie Y
Endocr J; 2021 Jun; 68(6):729-738. PubMed ID: 33642418
[TBL] [Abstract][Full Text] [Related]
16. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Stoimenis D; Karagiannis T; Katsoula A; Athanasiadou E; Kazakos K; Bekiari E; Matthews DR; Tsapas A
Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a meta-analysis.
Chen Y; Men K; Li XF; Li J; Liu M; Fan ZQ
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3502-3514. PubMed ID: 29917205
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic safety of DPP-4 inhibitors in type 2 diabetes millitus: A protocol for systematic review and network meta-analysis.
Yang F; Dong Y; Li B; Ning B; Zhao Q
Medicine (Baltimore); 2022 Apr; 101(17):e29154. PubMed ID: 35512071
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants.
Li Z; Lin C; Zhou J; Cai X; Zhu X; Hu S; Lv F; Yang W; Ji L
Expert Opin Investig Drugs; 2022 Sep; 31(9):957-964. PubMed ID: 35968648
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
